Cardano Risk Management B.V. Has $230.72 Million Stock Holdings in Eli Lilly and Company $LLY

Cardano Risk Management B.V. decreased its position in Eli Lilly and Company (NYSE:LLY) by 89.4% during the 1st quarter, Holdings Channel reports. The firm owned 250,841 shares of the company’s stock after selling 2,124,209 shares during the quarter. Eli Lilly and Company makes up 2.3% of Cardano Risk Management B.V.’s investment portfolio, making the stock its 11th biggest holding. Cardano Risk Management B.V.’s holdings in Eli Lilly and Company were worth $230,716,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in LLY. Maryland Capital Advisors Inc. bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Osbon Capital Management LLC acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $25,000. Basso Capital Management L.P. acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $30,000. Miller Global Investments LLC bought a new position in Eli Lilly and Company in the 4th quarter valued at $33,000. Finally, E Fund Management Hong Kong Co. Ltd. raised its position in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of several research reports. Rothschild & Co Redburn upped their price target on shares of Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Barclays boosted their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Monday, May 4th. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 8th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,235.07.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand Lilly’s oncology revenue opportunity in the EU. Article Title
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with new details on the Medicare GLP-1 Bridge program that could broaden access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1. Article Title
• Positive Sentiment: Management’s expanded access push and continued clinical progress in obesity/diabetes are reinforcing the view that Lilly remains a leader in the weight-loss drug race, supporting bullish sentiment. Article Title
• Neutral Sentiment: Some recent coverage highlights Lilly’s strong pipeline and market leadership, but also notes valuation concerns and a less attractive entry point after the stock’s big run. Article Title
• Neutral Sentiment: News about Lilly launching its cancer drug Tanstrive in India adds another growth angle, but it appears to be a smaller near-term stock driver than the obesity and EU approval updates. Article Title

Eli Lilly and Company Trading Up 7.0%

Shares of NYSE LLY opened at $1,206.51 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,215.76. The firm has a market capitalization of $1.14 trillion, a P/E ratio of 42.86, a P/E/G ratio of 1.23 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company’s 50 day simple moving average is $1,036.28 and its 200 day simple moving average is $1,020.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the business posted $3.34 EPS. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts predict that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.